Detalhe da pesquisa
1.
Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom.
Br J Cancer
; 2024 Apr 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38658782
2.
The emerging predictive and prognostic role of HER2 in HER2-negative early breast cancer: a retrospective study.
Breast Cancer Res Treat
; 2024 May 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38743174
3.
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
N Engl J Med
; 382(7): 597-609, 2020 02 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31825569
4.
Neratinib in advanced HER2-positive breast cancer: experience from the royal Marsden hospital.
Breast Cancer Res Treat
; 195(3): 333-340, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35976513
5.
Clinical outcomes in patients with triple negative or HER2 positive lobular breast cancer: a single institution experience.
Breast Cancer Res Treat
; 192(3): 563-571, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35119530
6.
A review on the added value of whole-body MRI in metastatic lobular breast cancer.
Eur Radiol
; 32(9): 6514-6525, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35384456
7.
EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers.
Gut
; 70(9): 1632-1641, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33199443
8.
Impact of timing of adjuvant chemothapy for early breast cancer: the Royal Marsden Hospital experience.
Br J Cancer
; 125(2): 299-304, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34017085
9.
COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study.
Lancet
; 395(10241): 1919-1926, 2020 06 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-32473682
10.
Pathological complete response to neoadjuvant systemic therapy in 789 early and locally advanced breast cancer patients: The Royal Marsden experience.
Breast Cancer Res Treat
; 179(1): 101-111, 2020 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-31535318
11.
Developing therapies for triple-negative breast cancer subtypes.
Lancet Oncol
; 25(2): 149-151, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38211607
12.
Development and responses of brain metastases during treatment with trastuzumab emtansine (T-DM1) for HER2 positive advanced breast cancer: A single institution experience.
Breast J
; 24(3): 253-259, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28833867
13.
Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial.
Lancet Oncol
; 18(9): 1249-1260, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28784312
14.
Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial.
Lancet Oncol
; 18(3): 357-370, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28163000
15.
Resolution of severe hyponatraemia is associated with improved survival in patients with cancer.
BMC Cancer
; 15: 163, 2015 Mar 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-25885450
16.
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial.
Lancet Oncol
; 14(6): 481-9, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23594787
17.
Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer.
Clin Cancer Res
; 30(4): 895-903, 2024 02 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38078899
18.
Systemic Therapy for Metastatic Triple Negative Breast Cancer: Current Treatments and Future Directions.
Cancers (Basel)
; 15(15)2023 Jul 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37568617
19.
Systemic Therapies for HER2-Positive Advanced Breast Cancer.
Cancers (Basel)
; 16(1)2023 Dec 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38201451
20.
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study.
J Clin Oncol
; 41(36): 5569-5578, 2023 Dec 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37751561